AstraZeneca PLC (AZN)vsNeuropace Inc (NPCE)
AZN
AstraZeneca PLC
$160.17
+0.33%
HEALTHCARE · Cap: $252.33B
NPCE
Neuropace Inc
$14.04
+1.23%
HEALTHCARE · Cap: $511.43M
Smart Verdict
WallStSmart Research — data-driven comparison
AstraZeneca PLC generates 57255% more annual revenue ($61.37B vs $106.99M). AZN leads profitability with a 17.0% profit margin vs -17.9%. AZN earns a higher WallStSmart Score of 60/100 (C+).
AZN
Buy60
out of 100
Grade: C+
NPCE
Avoid27
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+18.4%
Fair Value
$196.10
Current Price
$160.17
$35.93 discount
Margin of Safety
-17.2%
Fair Value
$12.42
Current Price
$14.04
$1.62 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 21 in profit
Strong operational efficiency at 23.5%
Generating 2.1B in free cash flow
17.1% revenue growth
Areas to Watch
2.5% earnings growth
Distress zone — elevated risk
0.0% earnings growth
Smaller company, higher risk/reward
Trading at 40.1x book value
ROE of -160.8% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : AZN
The strongest argument for AZN centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 17.0% and operating margin at 23.5%. PEG of 1.28 suggests the stock is reasonably priced for its growth.
Bull Case : NPCE
The strongest argument for NPCE centers on Revenue Growth. Revenue growth of 17.1% demonstrates continued momentum.
Bear Case : AZN
The primary concerns for AZN are EPS Growth, Altman Z-Score.
Bear Case : NPCE
The primary concerns for NPCE are EPS Growth, Market Cap, Price/Book. Debt-to-equity of 5.88 is elevated, increasing financial risk.
Key Dynamics to Monitor
AZN profiles as a mature stock while NPCE is a growth play — different risk/reward profiles.
NPCE carries more volatility with a beta of 1.95 — expect wider price swings.
NPCE is growing revenue faster at 17.1% — sustainability is the question.
AZN generates stronger free cash flow (2.1B), providing more financial flexibility.
Bottom Line
AZN scores higher overall (60/100 vs 27/100), backed by strong 17.0% margins. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AstraZeneca PLC
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AstraZeneca PLC discovers, develops, manufactures and markets prescription drugs in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infections, neuroscience and gastroenterology worldwide. The company is headquartered in Cambridge, the United Kingdom.
Neuropace Inc
HEALTHCARE · MEDICAL DEVICES · USA
NeuroPace, Inc. is a medical device company in the United States. The company is headquartered in Mountain View, California.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?